Moderna shares hit $192.31 as cancer pipeline reshapes investor focus
AI Summary- Moderna highlighted intismeran autogene and oncology as central to its post-COVID strategy.
- $192.31 marked Moderna’s Wednesday 52-week high before shares closed down 0.3%.
- Moderna raised $2.6 billion and currently markets five authorized vaccines, with two launches planned.